Lilly’s Once-Weekly Insulin Cuts A1C, Matches Daily Insulin Safety in Phase 3 Trials
Eli Lilly and Company has announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily
